1. Centralförbundet för alkohol- och narkotikaupplysning (CAN). Negativa konsekvenser av alkohol, narkotika och tobak – en studie med fokus på beroende och problem från andras konsumtion i Sverige 2017. Stockholm, Sverige; 2018.
2. Leifman H, Rehnman C, Sjoblom E, Holgersson S. Anabolic androgenic steroids--use and correlates among gym users--an assessment study using questionnaires and observations at gyms in the Stockholm region. Int J Environ Res Public Health. 2011 Jul;8(7):2656–74.
3. Backhouse S, Collins C, Defoort Y, McNamee M, Parkinson A SM, Brissonneau C, Christensen A, Dikic N HD. Study on Doping Prevention: A map of Legal, Regulatory and Prevention Practice Provisions in EU 28 [Internet]. 2014. Available from: http://ec.europa.eu/assets/eac/sport/news/2014/docs/doping-prevention-report_en.pdf
4. Goldman A, Basaria S. Adverse health effects of androgen use. Mol Cell Endocrinol [Internet]. 2017/06/14. 2017; Available from: https://www.ncbi.nlm.nih.gov/pubmed/28606866
5. Frati P, Busardo FP, Cipolloni L, Dominicis ED, Fineschi V. Anabolic Androgenic Steroid (AAS) related deaths: autoptic, histopathological and toxicological findings. Curr Neuropharmacol [Internet]. 2015/06/16. 2015;13(1):146–59. Available from: https://www.ncbi.nlm.nih.gov/pubmed/26074749
6. Casavant MJ, Blake K, Griffith J, Yates A, Copley LM. Consequences of use of anabolic androgenic steroids. Pediatr Clin North Am [Internet]. 2007/08/29. 2007;54(4):677–90, x. Available from: https://www.ncbi.nlm.nih.gov/pubmed/17723870
7. Yesalis CE, Bahrke MS. Doping among adolescent athletes. Baillieres Best Pr Res Clin Endocrinol Metab [Internet]. 2000/08/10. 2000;14(1):25–35. Available from: https://www.ncbi.nlm.nih.gov/pubmed/10932808
8. Turillazzi E, Perilli G, Di Paolo M, Neri M, Riezzo I, Fineschi V. Side effects of AAS abuse: an overview. Mini Rev Med Chem [Internet]. 2011/03/30. 2011;11(5):374–89. Available from: https://www.ncbi.nlm.nih.gov/pubmed/21443513
9. Basaria S. Androgen abuse in athletes: detection and consequences. J Clin Endocrinol Metab [Internet]. 2010/02/09. 2010;95(4):1533–43. Available from: https://www.ncbi.nlm.nih.gov/pubmed/20139230
10. Thiblin I, Garmo H, Garle M, Holmberg L, Byberg L, Michaelsson K, et al. Anabolic steroids and cardiovascular risk: A national population-based cohort study. Drug Alcohol Depend [Internet]. 2015/05/26. 2015;152:87–92. Available from: https://www.ncbi.nlm.nih.gov/pubmed/26005042
11. Parkinson AB, Evans NA. Anabolic androgenic steroids: a survey of 500 users. Med Sci Sport Exerc [Internet]. 2006/05/09. 2006;38(4):644–51. Available from: https://www.ncbi.nlm.nih.gov/pubmed/16679978
12. Thiblin I, Lindquist O, Rajs J. Cause and manner of death among users of anabolic androgenic steroids. J Forensic Sci [Internet]. 2000/01/21. 2000;45(1):16–23. Available from: https://www.ncbi.nlm.nih.gov/pubmed/10641914
13. Fineschi V, Riezzo I, Centini F, Silingardi E, Licata M, Beduschi G, et al. Sudden cardiac death during anabolic steroid abuse: morphologic and toxicologic findings in two fatal cases of bodybuilders. Int J Leg Med [Internet]. 2005/11/18. 2007;121(1):48–53. Available from: https://www.ncbi.nlm.nih.gov/pubmed/16292586
14. Luke JL, Farb A, Virmani R, Sample RH. Sudden cardiac death during exercise in a weight lifter using anabolic androgenic steroids: pathological and toxicological findings. J Forensic Sci [Internet]. 1990/11/01. 1990;35(6):1441–7. Available from: https://www.ncbi.nlm.nih.gov/pubmed/2148179
15. Pope HGJ, Katz DL. Psychiatric and medical effects of anabolic-androgenic steroid use. A controlled study of 160 athletes. Arch Gen Psychiatry. 1994 May;51(5):375–82.
16. Kanayama G, Pope HG, Cohane G, Hudson JI. Risk factors for anabolic-androgenic steroid use among weightlifters: a case-control study. Drug Alcohol Depend [Internet]. 2003/06/25. 2003;71(1):77–86. Available from: https://www.ncbi.nlm.nih.gov/pubmed/12821208
17. FOHM. Handledning för litteraturöversikter. Stockholm; 2017.
18. Andrén-Sandberg Å. Anti-doping – In an era of evidence based medicine. 2017.
19. Centralförbundet för alkohol- och narkotikaupplysning (CAN). Skolelevers drogvanor 2018, CAN rapport 178. Stockholm, Sverige; 2018.
20. Rasmussen JJ, Selmer C, Østergren PB, Pedersen KB, Schou M, Gustafsson F, et al. Former Abusers of Anabolic Androgenic Steroids Exhibit Decreased Testosterone Levels and Hypogonadal Symptoms Years after Cessation: A Case-Control Study. PLoS One. 2016;11(8):e0161208.
21. Burstrom K, Johannesson M, Diderichsen F. Swedish population health-related quality of life results using the EQ-5D. Qual Life Res. 2001;10(7):621–35.
22. Petek D, Petek-Ster M, Tusek-Bunc K. Health Behavior and Health-related Quality of Life in Patients with a High Risk of Cardiovascular Disease. Zdr Varst. 2018 Mar;57(1):39–46.
23. Arver S, Luong B, Fraschke A, Ghatnekar O, Stanisic S, Gultyev D, et al. Is testosterone replacement therapy in males with hypogonadism cost-effective? An analysis in Sweden. J Sex Med. 2014 Jan;11(1):262–72.
24. Sobocki P, Ekman M, Agren H, Krakau I, Runeson B, Mårtensson B, et al. Health-related quality of life measured with EQ-5D in patients treated for depression in primary care. Value Health [Internet]. 2007;10(2):153–60. Available from: https://www.ncbi.nlm.nih.gov/pubmed/17391424
25. Allgulander C, Florea I, Huusom AKT. Prevention of relapse in generalized anxiety disorder by escitalopram treatment. Int J Neuropsychopharmacol. 2006 Oct;9(5):495–505.
26. Hakkaart-van Roijen L, Hoeijenbos MB, Regeer EJ, ten Have M, Nolen WA, Veraart CPWM, et al. The societal costs and quality of life of patients suffering from bipolar disorder in the Netherlands. Acta Psychiatr Scand. 2004 Nov;110(5):383–92.
27. Chong CAKY, Li S, Nguyen GC, Sutton A, Levy MH, Butler T, et al. Health-state utilities in a prisoner population: a cross-sectional survey. Health Qual Life Outcomes. 2009 Aug;7:78.
28. Statens folkhälsoinstitut. Dopning i samhället - Vad? Hur? Vem? Varför? 2011.
29. Statistiska Centralbyrån. Tre av fyra idrottar på fritiden. 2017.
30. Statistics Sweden [Statistiska centralbyrån]. Population by region, marital status, age and sex. Year 1968 - 2018 [Folkmängden efter region, civilstånd, ålder och kön. År 1968 - 2018] [Internet]. Available from: http://www.statistikdatabasen.scb.se/pxweb/en/ssd/START__BE__BE0101__BE0101A/BefolkningNy/?rxid=f8cac331-5bd6-42d2-91b1-3cd14a994358
31. Folkhälsomyndigheten. Länsrapportens undersökning 2017: Länsstyrelsens ANDT‐samordning. Stockholm, Sweden; 2017.
32. Folkhälsomyndigheten. Länsrapport 2017: Kommunernas ANDT-förebyggande arbete. Stockholm, Sweden; 2017.
33. Socialdepartementet. Förordning om samordning inom alkohol-, narkotika-, dopnings- och tobaksområdet m.m. Sverige; 2012.
34. Socialdepartementet. Regleringsbrev för budgetåret 2019 avseende anslag 6:1. S2018/06066/RS Sverige; 2019.
35. Johannesson M, Borgquist L, Jonsson B. The costs of treating hypertension in Sweden. An empirical investigation in primary health care. Scand J Prim Health Care. 1991 Sep;9(3):155–60.
36. Gouveia M, Borges M, Costa J, Oliveira E, David C, Carneiro AV. Costs of illness due to hypeercholesterolemia in Portugal. Rev Port Cardiol. 2004;23(7–8):1037–54.
37. Muller-Nordhorn J, Englert H, Wegscheider K, Berger H, Sonntag F, Voller H, et al. Productivity loss as a major component of disease-related costs in patients with hypercholesterolemia in Germany. Clin Res Cardiol. 2008 Mar;97(3):152–9.
38. Hepp Z, Kim G, Lenhart G, Johnson BH. Absenteeism and Indirect Economic Burden Associated With Primary and Secondary Hypogonadism: A Retrospective Matched Cohort Analysis of Employed, Commercially Insured Patients in the U.S. J Occup Environ Med. 2018 Aug;60(8):724–31.
39. Kaltenboeck A, Foster S, Ivanova J, Diener M, Bergman R, Birnbaum H, et al. The direct and indirect costs among US privately insured employees with hypogonadism. J Sex Med [Internet]. 2012 Sep;9(9):2438–47. Available from: https://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2012-24308-027&site=ehost-live
40. Andlin-Sobocki P, Wittchen H-U. Cost of affective disorders in Europe. Eur J Neurol. 2005 Jun;12 Suppl 1:34–8.
41. Luppa M, Heinrich S, Angermeyer MC, König HH, Riedel-Heller SG. Cost-of-illness studies of depression. A systematic review. J Affect Disord. 2007;98(1–2):29–43.
42. Ekman M, Granstrom O, Omerov S, Jacob J, Landen M. The societal cost of depression: evidence from 10,000 Swedish patients in psychiatric care. J Affect Disord. 2013 Sep;150(3):790–7.
43. Sandelin R, Kowalski J, Ahnemark E, Allgulander C. Treatment patterns and costs in patients with generalised anxiety disorder: one-year retrospective analysis of data from national registers in Sweden. Eur Psychiatry. 2013 Feb;28(2):125–33.
44. Ekman M, Granstrom O, Omerov S, Jacob J, Landen M. The societal cost of bipolar disorder in Sweden. Soc Psychiatry Psychiatr Epidemiol. 2013 Oct;48(10):1601–10.
45. The Swedish Prison and Probation Service [Kriminalvården]. Kriminalvårdens årsredovisning 2018 [Internet]. 2018. Available from: https://www.kriminalvarden.se/om-kriminalvarden/publikationer/ekonomi/arsredovisning-2018/
46. The Swedish National Council for Crime Prevention [Brottsförebyggande rådet]. Kortanalys 2015:4. Utdömda strafftider - en jämförelse av fullbordade brott och försöksbrott. Nio utvalda brottstyper 2000-2013 [Internet]. 2015. Available from: https://www.bra.se/publikationer/kortanalyser.html
47. Statistics Sweden [Statistiska centralbyrån]. Lönedatabasen [Salary database] [Internet]. 2016. Available from: http://www.scb.se/
48. Region Örebro Län. Dopning: Översikt, vård och behandling samt idéskiss till ett nationellt kompetenscentrum. Slutrapport från Nationellt kompetensutvecklingsprojekt för dopningsproblematik (NKD) - 2013-2015. Örebro, Sweden; 2016.
49. Lindqvist Bagge AS, Rosén T, Fahlke C, Ehrnborg C, Eriksson BO, Moberg T, et al. Somatic effects of AAS abuse: A 30-years follow-up study of male former power sports athletes. J Sci Med Sport. 2017 Sep;20(9):814–8.
50. Central Agency for Information on Alcohol and Drugs. Skolelevers drogvanor 2018 (School Students Drug Use 2018). 2018.
51. Molero Y, Gripenberg J, Bakshi A-S. Effectiveness and implementation of a community-based prevention programme targeting anabolic androgenic steroid use in gyms: study protocol of a quasi-experimental control group study. BMC Sport Sci Med Rehabil [Internet]. 2016 Nov 17;8:36. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27891233
52. Public Health Agency of Sweden [Folkhälsomyndigheten]. Sjukdomar och övriga besvär. Nationella folkhälsoenkäten, nationella och regionala resultat. [Internet]. Available from: https://www.folkhalsomyndigheten.se/folkhalsorapportering-statistik/statistikdatabaser-och-visualisering/nationella-folkhalsoenkaten/fysisk-halsa/sjukdomar-och-ovriga-besvar/
53. Stockholm Region [Stockholms län landsting]. Folkhälsorapport 2015. Folkhälsan i Stockholms län. 2015;
54. Zarotsky V, Huang M-Y, Carman W, Morgentaler A, Singhal PK, Coffin D, et al. Systematic literature review of the risk factors, comorbidities, and consequences of hypogonadism in men. Andrology. 2014 Nov;2(6):819–34.
55. Murray CJL, Barber RM, Foreman KJ, Ozgoren AA, Abd-Allah F, Abera SF, et al. Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990–2013: quantifying the epidemiological transition. Lancet. 2015;386(10009):2145–91.
56. The Swedish National Council for Crime Prevention [Brottsförebyggande rådet]. Persons sentenced to imprisonment and admitted to prison 2017, by principal offence, age and gender. [Internet]. 2017. Available from: https://www.bra.se/bra-in-english/home/crime-and-statistics/crime-statistics.html